## I-Tsu Chyuan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1726351/publications.pdf

Version: 2024-02-01

567281 752698 21 557 15 20 citations h-index g-index papers 22 22 22 1053 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	T Cell–Specific Deletion of TRAIL Receptor Reveals Its Critical Role for Regulating Pathologic T Cell Activation and Disease Induction in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2022, 208, 1534-1544.	0.8	О
2	Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus. Cellular and Molecular Immunology, 2021, 18, 1772-1782.	10.5	14
3	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. Cancers, 2021, 13, 1188.	3.7	27
4	Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation. Cancers, 2021, 13, 1253.	3.7	11
5	Immunometabolism in systemic lupus erythematosus: Relevant pathogenetic mechanisms and potential clinical applications. Journal of the Formosan Medical Association, 2021, 120, 1667-1675.	1.7	7
6	Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. Biochemical Pharmacology, 2021, 193, 114760.	4.4	42
7	Lovastatinâ€mediated MCFâ€7 cancer cell death involves LKB1â€AMPKâ€p38MAPKâ€p53â€survivin signalling cas Journal of Cellular and Molecular Medicine, 2020, 24, 1822-1836.	scade. 3.6	40
8	New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochemical Pharmacology, 2020, 175, 113928.	4.4	51
9	TRAIL regulates T cell activation and suppresses inflammation in autoimmune diseases. Cellular and Molecular Immunology, 2020, 17, 1281-1283.	10.5	9
10	Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. Cells, 2019, 8, 963.	4.1	50
11	TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment. Cell Death and Disease, 2019, 10, 77.	6.3	25
12	Shaping of Innate Immune Response by Fatty Acid Metabolite Palmitate. Cells, 2019, 8, 1633.	4.1	34
13	Tumor necrosis factor: The key to hepatitis B viral clearance. Cellular and Molecular Immunology, 2018, 15, 731-733.	10.5	12
14	An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T-cell activation in inflammatory arthritis. Cellular and Molecular Immunology, 2018, 15, 846-857.	10.5	34
15	Significant association of rheumatoid arthritis-related inflammatory markers withÂnon-surgical periodontal therapy. Journal of the Formosan Medical Association, 2018, 117, 1003-1010.	1.7	22
16	Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. Mediators of Inflammation, 2018, 2018, 1-8.	3.0	30
17	TRAIL-Mediated Suppression of T Cell Receptor Signaling Inhibits T Cell Activation and Inflammation in Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2018, 9, 15.	4.8	35
18	Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis. Journal of Molecular Medicine, 2016, 94, 545-556.	3.9	34

## I-Tsu Chyuan

#	Article	IF	CITATIONS
19	Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice. Rheumatology, 2015, 54, 1317-1326.	1.9	32
20	β2â€Glycoprotein lâ€Dependent Antiâ€Cardiolipin Antibodies Associated With Periodontitis in Patients With Systemic Lupus Erythematosus. Journal of Periodontology, 2015, 86, 995-1004.	3.4	20
21	Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. Cellular and Molecular Immunology, 2015, 12, 317-325.	10.5	28